Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

ABBV-101

Small molecule · Degrader of Bruton's tyrosine kinase (BTK) · developed by AbbVie

Phase 1 Most advanced trial
ABBV Developer
1 Registered trials

What is ABBV-101?

ABBV-101 is an orally bioavailable protein degrader that links an E3 ubiquitin ligase binder to a BTK-binding moiety. It drives ubiquitination and proteasomal degradation of Bruton's tyrosine kinase, blocking B-cell receptor signaling in malignant B-cells. It is being studied in hematologic cancer.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Small molecule
Targets
Bruton's tyrosine kinase (BTK)
Mechanism
Degrader of Bruton's tyrosine kinase (BTK)
Pathways
B-cell antigen receptor signaling, BTK-mediated downstream survival signaling, ubiquitin-proteasome degradation
Therapy area
Oncology
Developer
AbbVie (ABBV)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT05753501 Phase 1 Hematologic Cancer Active not recruiting ABBV

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Hematologic Cancer

Other drugs acting on BTK

More from AbbVie

Sources

Updated Nov 8, 2026. Something wrong or missing? Report it on the ABBV page.

Follow ABBV, the company behind ABBV-101

See ABBV's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

ABBV catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.